In the EMILIA trial, patients with absent or decreased tumor PTEN expression derived greater benefit from T-DM1 than capecitabine and lapatinib compared to patients with normal or increased tumor PTEN expression [13]. This evidence concerns the gene PTEN and neoplasm.